EOLS
Evolus, Inc. Common Stock (EOLS)
Healthcare • Drug Manufacturers - Specialty & Generic • $5.73 • MCap: 377,347,744
🌐
https://www.evolus.com • Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Buy Decision Core
Total Score
44
Business Quality
10
Financial Strength
11
Growth Outlook
1
Momentum
3
Price Action
Current
5.73
52W High
9.65
52W Low
3.94
Above 50DMA
6.56 (-12.66%)
Above 200DMA
5.90 (-2.82%)
Relative Strength
Relative Strength
0.04
RS 3M
0.26
RS 6M
0.14
RS 9M
-0.1
RS 12M
-0.38
Fundamentals
Revenue Growth
0.07%
Earnings Growth
0%
ROE
0%
ROA
-0.09%
Valuation
PE (Fwd)
23.88
PEG
0
P/B
-13.11
Upside
155.96%
Risk
Beta
1.32
Short %
0.09
Risk Score
7.00
Analyst
Rating
strong_buy
Target
14.67
Beta
1.32
Analysts
0
Total Score
44
Upside
155.96%
Relative Strength
0.04
Beta
1.32
Why Buy?
- PEG Ratio below 1 (attractive valuation)
- Trading below book value
- Analyst upside exceeds 15%
Key Risks
- Weak long-term relative strength
Score Breakdown
Business
10
10
Financial
11
11
Growth
1
1
Valuation
13
13
Risk
2
2
Momentum
3
3
Technical
52W High: 9.65
52W Low: 3.94
Above 50DMA: -12.66%
Above 200DMA: -2.82%
Valuation
Forward PE: 23.88
PEG: 0
P/B: -13.11
Upside: 155.96%
Risk
Beta: 1.32
Short Float: 0.09%
ROE: 0%
ROA: -0.09%